Cite
HARVARD Citation
Friedlander, M. et al. (2018). Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet oncology. 19 (8), pp. 1126-1134. [Online].